Italian network for people with islet autoantibodies
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study follows people who have islet autoantibodies (markers in the blood that can increase the risk of type 1 diabetes) but do not have diabetes yet. The goal is to better understand how these antibodies affect health over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must have tested positive for at least one islet autoantibody in the blood.
- You must not have any symptoms of diabetes, such as frequent urination, excessive thirst, or unexplained weight loss.
- You must not meet the standard diagnosis for diabetes, like high blood sugar or A1c levels.
- You must be willing to attend follow-up visits and tests as part of the study.
- You or a parent/guardian (for minors) must sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls people with islet autoantibodies, which are early markers for type 1 diabetes. It aims to understand who develops these antibodies and how they are linked to diabetes over time. No treatment is given—you just provide blood samples and answer questions.
This study checks if people with autoimmune thyroid disease may also be at risk for developing type 1 diabetes. It looks at the body's attack on insulin-producing cells in the pancreas, using blood tests to catch early signs.
This study looks at stored blood samples from adults with type 1 diabetes to understand how a protein called GLUT1 affects the immune system. The goal is to find new ways to control autoimmunity, which could lead to better treatments.
This study tests a new treatment called E-islet 01, which may help people with type 1 diabetes who have very low natural insulin production and have had dangerous low blood sugar events. The goal is to see if it is safe and can reduce those episodes.
This early study tests a new kind of donor islet transplant (UP421) designed to avoid rejection. It's for adults with long-standing type 1 diabetes who have trouble controlling blood sugar despite intensive insulin therapy.
This study measures “circulating biomarkers” (blood-based signals) in people with type 1 or type 2 diabetes, and in some people without diabetes who test positive for certain diabetes antibodies. The goal is to understand what these blood signals can tell us about diabetes development and progression.
Hear when a new Autoantibodies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.